Successful encorafenib desensitization in a patient with recurrent metastatic melanoma

We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.
Source: Melanoma Research - Category: Cancer & Oncology Tags: Short Communications Source Type: research